TD Cowen Maintains Buy on Standard BioTools, Lowers Price Target to $2.5
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Daniel Brennan maintains a Buy rating on Standard BioTools (NASDAQ:LAB) but lowers the price target from $2.75 to $2.5.
October 31, 2024 | 5:11 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
TD Cowen analyst Daniel Brennan maintains a Buy rating on Standard BioTools but lowers the price target from $2.75 to $2.5, indicating a slight decrease in expected valuation.
The Buy rating suggests continued confidence in the stock's potential, but the lowered price target indicates a slight reduction in expected valuation. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100